<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289574</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-J9-202</org_study_id>
    <nct_id>NCT01289574</nct_id>
  </id_info>
  <brief_title>Topical ASC-J9 Cream for Acne</brief_title>
  <official_title>Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of 0.1% and 0.025% ASC-J9 Creams Applied Topically Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AndroScience Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orient Europharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AndroScience Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice
      daily for facial acne compared to vehicle control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 180 patients at least 12 years of age with facial acne will be randomized to
      twice daily topical treatment with 0.1% or 0.025% ASC-J9 cream or vehicle control for 12
      weeks. Patients will return to the clinic at Weeks 2, 4, 8 and 12 and again 4 weeks after the
      last dose of study drug for evaluation of acne status and safety parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Inflammatory Acne Lesion Counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success on Investigator Global Assessment (IGA) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall acne rated as clear, almost clear, mild, moderate, severe, very severe.
Success = Week 12 rating of clear or almost clear and at least a 2-grade improvement from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Noninflammatory Acne Lesion Counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from Baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Vehicle control cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.025% ASC-J9 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% ASC-J9 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC-J9</intervention_name>
    <description>Cream for twice daily topical application to the face</description>
    <arm_group_label>Vehicle control cream</arm_group_label>
    <arm_group_label>0.025% ASC-J9 cream</arm_group_label>
    <arm_group_label>0.1% ASC-J9 cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  At least 12 years of age at the time of enrollment

          -  Facial acne, with:

               1. 20-60 inflammatory facial lesions (papules/pustules/nodules/cysts);

               2. 20-100 noninflammatory facial lesions (open and closed comedones);

               3. No more than 2 nodules/cysts on the face (defined as an inflammatory lesion
                  greater than or equal to 5 mm in diameter);

               4. Investigator's Global Assessment (IGA) acne score of 3 or 4.

        Key Exclusion Criteria:

          -  Females who are pregnant or breast-feeding

          -  Skin diseases other than acne vulgaris

          -  Use of other topical or systemic treatments for acne

          -  Other significant medical conditions or clinically significant abnormal laboratory
             test results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Dosik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chieh-Chen Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shih Kong Wu Ho-Su Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Hsun Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting-Jui Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wan Fang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei-Ming Wang, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kuo-Hsien Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji-Chen Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital Kaohsiung Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Research, Inc</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>NiaoSong District</city>
        <state>Kaohsiung City</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shih Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11160</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch</name>
      <address>
        <city>Gueishan Township</city>
        <state>Taoyuan County</state>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11696</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>June 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2014</results_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>androgen receptor degradation enhancer</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vehicle Control Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="P2">
          <title>0.025% ASC-J9 Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="P3">
          <title>0.1% ASC-J9 Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject wanted alternate treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Vehicle Control Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="B2">
          <title>0.025% ASC-J9 Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="B3">
          <title>0.1% ASC-J9 Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="5.7"/>
                    <measurement group_id="B2" value="20.7" spread="4.8"/>
                    <measurement group_id="B3" value="22.0" spread="6.3"/>
                    <measurement group_id="B4" value="21.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Inflammatory Acne Lesion Counts</title>
        <description>Percent change from Baseline</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Control Cream</title>
            <description>Vehicle control cream for twice daily topical application to the face</description>
          </group>
          <group group_id="O2">
            <title>0.025% ASC-J9 Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
          <group group_id="O3">
            <title>0.1% ASC-J9 Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inflammatory Acne Lesion Counts</title>
          <description>Percent change from Baseline</description>
          <population>All randomized patients</population>
          <units>Percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="52.2"/>
                    <measurement group_id="O2" value="-44.3" spread="31.7"/>
                    <measurement group_id="O3" value="-44.4" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1919</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) row mean score statistics, adjusting for investigational site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success on Investigator Global Assessment (IGA) at Week 12</title>
        <description>Overall acne rated as clear, almost clear, mild, moderate, severe, very severe.
Success = Week 12 rating of clear or almost clear and at least a 2-grade improvement from baseline</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Control Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
          <group group_id="O2">
            <title>0.025% ASC-J9 Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
          <group group_id="O3">
            <title>0.1% ASC-J9 Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
        </group_list>
        <measure>
          <title>Success on Investigator Global Assessment (IGA) at Week 12</title>
          <description>Overall acne rated as clear, almost clear, mild, moderate, severe, very severe.
Success = Week 12 rating of clear or almost clear and at least a 2-grade improvement from baseline</description>
          <population>All randomized subjects</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0610</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Noninflammatory Acne Lesion Counts</title>
        <description>Percent change from Baseline</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Control Cream</title>
            <description>Vehicle control cream for twice daily topical application to the face</description>
          </group>
          <group group_id="O2">
            <title>0.025% ASC-J9 Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
          <group group_id="O3">
            <title>0.1% ASC-J9 Cream</title>
            <description>ASC-J9: Cream for twice daily topical application to the face</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Noninflammatory Acne Lesion Counts</title>
          <description>Percent change from Baseline</description>
          <population>All randomized subjects</population>
          <units>Percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5" spread="49.7"/>
                    <measurement group_id="O2" value="-35.5" spread="39.7"/>
                    <measurement group_id="O3" value="-36.3" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0857</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>During 12-week dosing period and for 4 weeks after the last dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vehicle Control Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="E2">
          <title>0.025% ASC-J9 Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
        <group group_id="E3">
          <title>0.1% ASC-J9 Cream</title>
          <description>ASC-J9: Cream for twice daily topical application to the face</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles CY Shih, PhD</name_or_title>
      <organization>AndroScience Corp</organization>
      <phone>(858) 638-7230</phone>
      <email>cyshih@androscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

